AUTHOR=Yuan Jinna , Fu Junfen , Wei Haiyan , Zhang Gaixiu , Xiao Yanfeng , Du Hongwei , Gu Wei , Li Yanhong , Chen Linqi , Luo Feihong , Zhong Yan , Gong Haihong 

TITLE=A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature

JOURNAL=Frontiers in Endocrinology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.864908

DOI=10.3389/fendo.2022.864908

ISSN=1664-2392

ABSTRACT=<sec><title>Background</title><p>To evaluate the safety and efficacy of daily somatropin (Jintropin<sup>®</sup>), a recombinant human growth hormone, in prepubertal children with ISS in China.</p></sec><sec><title>Methods</title><p>This study was a multicenter, randomized, controlled, open-label, phase 3 study. All subjects were randomized 3:1 to daily somatropin 0.05 mg/kg/day or no treatment for 52 weeks. A total of 481 subjects with a mean baseline age of 5.8 years were enrolled in the study. The primary endpoint was change in (△) height standard deviation score (HT-SDS) for chronological age (CA). Secondary endpoints included △height from baseline; △bone age (BA)/CA; △height velocity (HV) and △insulin-like growth factor 1 (IGF-1 SDS).</p></sec><sec><title>Results</title><p>△HT-SDS at week 52 was 1.04 ± 0.31 in the treatment group and 0.20 ± 0.33 in the control group (<italic>P</italic> &lt; 0.001). At week 52, statistical significance was observed in the treatment group compared with control for △height (10.19 ± 1.47 cm vs. 5.85 ± 1.80 cm; <italic>P</italic> &lt; 0.001), △BA/CA (0.04 ± 0.09 vs. 0.004 ± 0.01; <italic>P</italic> &lt; 0.001), △HV (5.17 ± 3.70 cm/year vs. 0.75 ± 4.34 cm/year; <italic>P</italic> &lt; 0.001), and △IGF-1 SDS (2.31 ± 1.20 vs. 0.22 ± 0.98; <italic>P</italic> &lt; 0.001). The frequencies of treatment-emergent adverse events (TEAEs) were similar for the treatment and the control groups (89.8% vs. 82.4%); most TEAEs were mild to moderate in severity and 23 AEs were considered study-drug related.</p></sec><sec><title>Conclusions</title><p>Daily subcutaneous administration of somatropin at 0.05 mg/kg/day for 52 weeks demonstrated improvement in growth outcomes and was well tolerated with a favorable safety profile.</p></sec><sec><title>Trial Registration</title><p><uri xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</uri> (identifier: NCT03635580). URL: <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT03635580" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT03635580</uri></p></sec>